JNPC Pharma Innovation Limited

JNPC Pharma Innovation Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN U73100TG2011PLC077628 Incorporated 23 November 2011 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Public Limited Company pharma
Revenue · FY 2025
₹1.6 Lakh
▼ 30% YoY
Net profit · FY 2025
₹1 Lakh
Net margin 62.5%
EBITDA · FY 2025
₹1.4 Lakh
EBITDA margin 87.5%
Authorised capital
₹25 Lakh
Registered with MCA
Paid-up capital
₹15 Lakh
Issued & subscribed
Company age
15 yrs
Est. 2011
Directors on board
3
As per MCA filings
Last financials
Mar 2025
Balance sheet date

About JNPC Pharma Innovation Limited

Data last updated:

JNPC Pharma Innovation Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Ramky Pharma City (India) Limited. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 23 November 2011 and has been in existence for over 15 years.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U73100TG2011PLC077628.

The company has an authorised share capital of ₹25 Lakh and a paid-up capital of ₹15 Lakh. It is led by directors including Yancharla Rathnakara Nagaraja and Popuri Pandari Lal Krishna.

Its last annual general meeting (AGM) was held on 10 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Ramky Grandiose 15th Floor Sy No 136/2 & 4 Gachibowli, Hyderabad, Telangana, India – 500032.

As per the financials filed for FY 2025, the company reported a revenue of ₹1.6 Lakh, a decline of 30% compared to the previous year. For the same year it recorded a net profit of ₹1 Lakh (net margin 62.5%) and EBITDA of ₹1.4 Lakh (EBITDA margin 87.5%). Revenue has grown at a compounded annual rate (CAGR) of 13% over three years and 3% over five years.

Court records list 1 case involving the company, including 1 filed against it; 1 case is pending. The company has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹10 Lakh; the latest was in March 2014.

The current compliance status is marked as compliant by the Registrar of Companies.

Company details

CIN U73100TG2011PLC077628
Registration Number 077628
Incorporation Date 23 November 2011
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Parent Company Ramky Pharma City (India) Limited
Compliance Status Active Compliant

CIN history

JNPC Pharma Innovation has one previous CIN (Corporate Identification Number): U73100AP2011PLC077628. The current CIN is U73100TG2011PLC077628, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U73100TG2011PLC077628Current
U73100AP2011PLC077628Previous

Contact details

JNPC Pharma Innovation Limited's registered office is in Hyderabad, Telangana. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Registered Address
    Ramky Grandiose 15th Floor Sy No 136/2 & 4 Gachibowli, Hyderabad, Telangana, India – 500032
  • Industry
    Pharma, Pharma Contract R&D

To see the full contact details of JNPC Pharma Innovation Limited, buy the company report.

Comprehensive company report
JNPC Pharma Innovation Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Financials of JNPC Pharma Innovation Limited

FY 2025 filings available

JNPC Pharma Innovation Limited reported revenue of ₹1.6 Lakh (down 30% YoY) for FY 2025.

Revenue · FY 2025
₹1.6 Lakh ▼ 30%
Net profit · FY 2025
₹1 Lakh margin 62.5%
EBITDA · FY 2025
₹1.4 Lakh margin 87.5%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▼ 30%
3 years · compounded
▲ 13%
5 years · compounded
▲ 3%
EBITDA CAGR growth
1 year
▼ 36%
3 years · compounded
▲ 16%
5 years · compounded
▲ 3%

Revenue fell 30% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 3%. EBITDA fell 36% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹1.4 Lakh
Profit Before Tax
Tax Expense
Net Profit (PAT)₹1 Lakh
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profitability
EBITDA Margin87.5%
Net Profit Margin62.5%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of JNPC Pharma Innovation Limited, buy the company report.

Board of directors of JNPC Pharma Innovation Limited

JNPC Pharma Innovation has 3 current directors and 11 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors

Auditor

JNPC Pharma Innovation Limited is audited by Visweswararao & Associates for the financial year 2016.

Auditor firmFinancial yearFirm registration number
Visweswararao & AssociatesFY 2016005774S

Shareholding

The shareholding of JNPC Pharma Innovation Limited is on record for 2 financial years, the latest being FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2017FY 2016
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of JNPC Pharma Innovation Limited, buy the company report.

Deals & funding

JNPC Pharma Innovation Limited has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹10 Lakh; the latest was in March 2014.

Total deals
2
Funding round
1
Secondary share transfer
1
Disclosed funding
₹10 Lakh

Deals on record (2 of 2)

WhenDealAmountParties
Mar 2014Secondary share transferUndisclosedBuyer: Visakha Pharmacity Limited
Seller: Smilax Laboratories Limited
Feb 2012Funding round₹10 LakhInvestors: Smilax Laboratories Limited

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for JNPC Pharma Innovation Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

No GST registration is on our record for JNPC Pharma Innovation Limited; the GSTIN and return-filing check is in the company report Buy the company report.

Recent activity

JNPC Pharma Innovation Limited has 14 board changes on record since 2012: 3 appointments and 11 cessations. The latest: Pakanati Venkata Raghava Reddy ceased to be Additional Director on 06 Sep 2024.

AGM
Jnpc Pharma Innovation Limited last Annual general meeting of members was held on 10 Sep 2025 as per latest MCA records.
Filing
Jnpc Pharma Innovation Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Ceased
Pakanati Venkata Raghava Reddy ceased to be Additional Director.
Appointed
Pakanati Venkata Raghava Reddy was appointed as Director.
Ceased
Ajay Kumar Masand ceased to be Additional Director.
Ceased
Yancharla Rathnakara Nagaraja ceased to be Additional Director.
Ceased
Sridhar Reddy Mandadi ceased to be Director.
Appointed
Yancharla Rathnakara Nagaraja was appointed as Director.
Ceased
Divakar Marri ceased to be Additional Director.
Ceased
Goutham Reddy Mareddy ceased to be Director.
Ceased
Popuri Pandari Lal Krishna ceased to be Additional Director.
Appointed
Popuri Pandari Lal Krishna was appointed as Director.

5 earlier events are in the company report.

Frequently asked questions

JNPC Pharma Innovation is an active public limited company based in Hyderabad, Telangana, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 23 November 2011 (15+ years old) and is registered under CIN U73100TG2011PLC077628.

JNPC Pharma Innovation has 3 current directors:

The latest financial statements of JNPC Pharma Innovation on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 10 September 2025. Year-wise statements from 2015 are in the company report.

The CIN (Corporate Identification Number) of JNPC Pharma Innovation is U73100TG2011PLC077628. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

JNPC Pharma Innovation has 1 court case on record: 1 filed against it. 1 is pending.

JNPC Pharma Innovation was incorporated on 23 November 2011, making it 15+ years old. It is registered with the Registrar of Companies, Hyderabad.

JNPC Pharma Innovation has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹10 Lakh; the latest was in March 2014.

Pakanati Venkata Raghava Reddy ceased to be Additional Director on 06 Sep 2024. Pakanati Venkata Raghava Reddy was appointed as Director on 05 Feb 2024. Ajay Kumar Masand ceased to be Additional Director on 29 Sep 2023. JNPC Pharma Innovation has 14 board changes on record in total.

The registered office of JNPC Pharma Innovation is at Ramky Grandiose 15th Floor Sy No 1362 & 4 Gachibowli, Hyderabad, Telangana, India – 500032.

JNPC Pharma Innovation operates in the pharma industry, in the pharma contract r and d segment.